Lacosamide Ucb (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes neuronal membranes and reduces repetitive firing. It also binds to CRMP‑2, a protein involved in neuronal development, providing an additional mechanism that contributes to seizure control.

The specific dose and infusion rate of Lacosamide Ucb are determined by the prescribing clinician based on the patient’s clinical condition, prior therapy, renal function, and other individual factors. Dosing recommendations are provided in the product’s prescribing information.

The safety of lacosamide during pregnancy and lactation has not been fully established. It is classified as pregnancy category unknown, and clinicians should consider potential risks versus benefits. Breastfeeding mothers should discuss possible exposure with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lacosamide has a unique mechanism that enhances slow sodium‑channel inactivation, differing from many older agents that target fast inactivation. This can provide additive seizure control when combined with other antiepileptics, and it is generally well tolerated, though cardiac monitoring may be needed in patients with pre‑existing conduction abnormalities.

Lacosamide Ucb should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution to maintain stability.

Lacosamide Ucb is given by intravenous infusion. The infusion rate and duration are set by the prescriber, typically administered over a period of several minutes to an hour, depending on the clinical protocol and patient tolerance.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation and atrial fibrillation, as well as rare severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for ECG changes and any signs of hypersensitivity during treatment.

Lacosamide Ucb is contraindicated in patients with known hypersensitivity to lacosamide or any component of the formulation. Caution is advised for individuals with significant cardiac conduction disorders, severe renal impairment, or those taking medications that markedly prolong the PR interval.